Swiss pharmaceutical giant Novartis International AG (NYSE: NVS) on Friday said its ofatumumab met the primary and secondary endpoints of Phase 3
Categories
clinical trials
CymaBay Therapeutics stock drops to 2-year low after bitter NASH study data
CymaBay Therapeutics (NASDAQ: CBAY) stock fell to a two-year low of $4.82 on Tuesday after disappointing nonalcoholic steatohepatitis (NASH) trial data. The
Solid Biosciences tumbles 38% to hit historic low
Shares of Solid Biosciences Inc. (NASDAQ: SLDB) opened 38% lower on Tuesday after the company said in its first-quarter results that its
Earnings: Affimed cuts down losses in 2018
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in 2018, helped
Aldeyra Therapeutics stock resumes trading, surges about 60% on positive trial results
After getting halted in Nasdaq for sometime, shares of Aldeyra Therapeutics (ALDX) resumed trading and climbed up about 60% during the pre-market
What is NASH and which biotech firms are vying for the first-mover status
NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver disorder is
Dermira stock doubles and hits new 52-week high on positive eczema trial results
Dermira Inc. (DERM) announced positive results from Phase 2b study for treating patients with atopic dermatitis, a condition which causes redness, dryness
Q4 Earnings Preview: All eyes on Neutrolin trial updates from CorMedix
Biopharma firm CorMedix (NYSE American: CRMD) has seen its shares skyrocket more than 500% in the last 12 months as investors are
Intercept stock surges on positive data from liver fibrosis drug study
Intercept Pharmaceuticals (ICPT) had surged about 25% in the pre-market session on Tuesday after the biopharma company announced positive topline results from
Gilead’s credibility takes a hit on massive NASH-drug failure, rivals jump
Shares of Gilead Sciences (GILD) have tumbled 20% in the past 52 weeks on numerous reasons including weaker-than-expected quarterly results and a